In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The New World Of Device Venture Investing: Same As The Old World?

Executive Summary

At Elsevier Business Intelligence's February IN3 West conference, a panel of leading device venture investors, who remain committed to and are actively doing deals in medtech, discussed how the recent recession has affected device investing and how much, if at all, that world has changed as a result.

You may also be interested in...



Percutaneous Intravascular Defibrillator Could Avert Common ICD Complications

A percutaneous intravascular cardioverter-defibrillator matched a conventional ICD in a randomized comparison of defibrillation thresholds. The authors of the study believe the PICD could reduce many of the complications associated with conventional defibrillators.

Medtech Risk Capital? Anything But. A VC Roundtable from IN3

A year and a half after the September 2008 collapse of Lehman Brothers and the official start of the economic recession, a panel of venture capitalists and other financiers in the medical device industry came together at the IN3 meeting in Boston. We asked them if they've had to change the way they look at deals. What is the trade-off between expensive, de-risked later stage deals and the kinds of returns that can be achieved by backing a winning company from start to finish? Where would they place their bets: cost-effective technologies for tried-and-true markets or novel products for unmet clinical needs, the "evolutionary vs. revolutionary" debate? And what can one do about tired syndicates? Our panel lets us in on the kinds of discussions they've been having around the table at weekly partners' meetings.

Device VCs Find New Hope in Old Exit Path

An analysis of acquisitions of privately held venture-backed medical device companies delivers some signs of hope as well as important warnings for medical device VCs hoping to find a lucrative exit in this difficult market.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

IV003629

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel